structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
29 sept. 2023 07h32 HE | Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
Orphai071d FINAL low res.jpg
AI Therapeutics Announces Name Change to OrphAI Therapeutics
28 sept. 2023 11h38 HE | AI Therapeutics, Inc.
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
03 août 2023 17h32 HE | Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics to Present at Jefferies Healthcare Conference
31 mai 2023 16h30 HE | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25 mai 2023 16h30 HE | Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...